A Phase 2 Extension of Study GCS-100-CS-4003

Summary

The primary objective of this study is to determine the safety and tolerability of extended dosing with a fixed dose of GCS-100 3 mg IV push in patients with Chronic Kidney Disease (CKD).

Timeline

Start

2015-01

Primary completion

2016-07

Completion

2016-07

Outcome

Outcome not reported

Stopped: “Corporate decision”

Drugs

Indications